Recon Strategy
Contact

Insights

Fifteen+ years of
Healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Sector
All
NEJM opinion

New class of therapeutics calls for new regulations: thoughts on the FDA’s new process for regulating digiceuticals

  • Medtech , 
  • Digital
Interest and investment in digital health has increased rapidly in rec…

Read more